anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the preparation of animal bone calcium, the main material of which is animal bone, belonging to the technical field of healthcare foods. The technical proposal is to provide a bone calcium with good water-solubility. The invention is characterized in that the components are as follows: total phosphorus calculated as P is 1.8 to 2.0%; calcium is 15 to 16%. The preparation method is: the enzymolysis liquid and the enzyme dissolved yak bone are obtained after the animal bone is cleaned, immersed, heated and enzyme dissolved; the dried zymolyte is obtained after the enzymolysis is degreased, filtered, and dried; the enzyme dissolved yak bone is dried and ground after being degreased; the dried zymolyte and ground animal bone is mixed in any proportion to get the bone calcium. The animal bone calcium has the advantages that the water-solubility is good; the absorption to human body is good; the calcium contents are high; the content of a plurality of amino acid necessary to human body is rich. In a word, the invention provides a new calcium supplement product and the preparation method. The popularization and application of the product is good for changing the calcium deficiency condition of human beings, especially Chinese and improving the health condition of human beings.
Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including meloxicam, in pregnant women at about 30 weeks gestation and later. NSAIDs, including meloxicam, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment

Use of NSAIDs, including meloxicam, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit meloxicam use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if meloxicam treatment extends beyond 48 hours. Discontinue meloxicam if oligohydramnios occurs and follow up according to clinical practice [see Use in Specific Populations (8.1)].
Participants will drink the placebo for 12 weeks. The placebo will be equicaloric and matched on appearance, taste, volume and macronutrient composition to the grape juice drink.
BACKGROUND/OBJECTIVES: In the origin and development of colorectal cancer (CRC), a global public health problem, a dysfunction mismatch repair system appears to be a key factor. The objective was to determine the association of intronic variants in the MSH2 and PMS2 genes with CRC in Mexican patients.
METHODS: Blood samples of 143 CRC patients and 146 reference individuals were genotyped through TaqMan® Genotyping Assays. Genotypic and allelic frequencies were determined by direct counting. To compare genotypic and allelic distributions, the chi-square test was used. For the association analysis, the risks of alleles and genotypes were estimated by odds ratio with 95% confidence intervals. Haplogroups were inferred with a Bayesian algorithm. Linkage disequilibrium was measured using D' and r2 with Arlequin v3.5.2. The in silico analysis was carried out using the SpliceAI, UCSC, JASPAR and TRRUST platforms. All statistical analyses were performed with SPSS v29.0.2.0.
RESULTS: In the CRC group, the mean age was 58.2 ± 14.7 years and 60.8% were men. No variant was associated with CRC or implicated in gene post-replicative processing. Linkage disequilibrium was observed for loci rs2303426 and rs10179950 in MSH2 and for loci rs2286681 and rs62456178 in PMS2.
CONCLUSIONS: The genotypic and allelic frequencies of the four variants are reported for the first time in Mexican patients with CRC. No association was found between gene variants and risk for CRC but there was a strong linkage disequilibrium between the loci of both MSH2 and PMS2 genes. None of the variants showed a possible repercussion on splicing.
PURPOSE: To analyze the value of ultrasonography in predicting metachronous contralateral inguinal hernia (MCIH) and diagnosing contralateral persistent processus vaginalis (CPPV) in children with unilateral inguinal hernia, a prospective study was conducted.
METHODS: All participants underwent a preoperative ultrasound on the contralateral groin. Patients in group A1 received operating procedure according to ultrasound results (patients with negative contralateral US results received hernia repair on the affected side), and patients in group A2 received operation according to laparoscopic results (patients received hernia repair and CPPV ligation). All patients were followed up 2 years and compared to a historical control (group B) who underwent open hernia repair only on the affected side regardless of contralateral US results.
RESULTS: In groups A1 and A2, laparoscopic exploration revealed the presence of a CPPV in 490 cases. Ultrasound was found to be accurate in 104 out of the 490 cases with four false-positive and 386 false-negative results. This yielded an accuracy of 59.3%, a sensitivity of 21.2%, and a specificity of 99.2%. 10 patients in group A1, and 74 patients in group B developed MCIH. The accuracy, sensitivity, and specificity of the value of ultrasonography in predicting MCIH were 89.3%, 52.4%, and 92.5%, respectively.
CONCLUSIONS: Preoperative ultrasonography of the contralateral groin is currently unable to accurately detect CPPV, but it appears to be a promising method in predicting MCIH by using rigorous diagnosing criteria.
For the pain-evoked potentials (PREPs), 20 additional healthy control subjects are to be included. Four subjects (2 male, 2 female) from each of the age decades 20-29, 30-39, 40-49, 50-59, 60-69.
Priapism is a painful and persistent erection, with or without sexual stimulation. A rare cause of such abnormality is chronic myeloid leukemia. Few cases of priapism as an initial manifestation of this type of leukemia have been reported in adolescent patients. Here we describe the case of a 16-year-old patient who presented with priapism as the initial manifestation of chronic myeloid leukemia. No cavernosal aspiration was performed. A specific hematological treatment was started and, given the persistence of priapism, the patient required 2 corpora cavernosa shunt procedures; despite this treatment, there is a high probability of sequelae.
Patients will undergo a routine 68Ga-DOTATATE PET/CT. Patients with sufficient tumor uptake will be offered therapy with 177Lu-DOTATATE. The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration.
PURPOSE:To provide the titled agent having low toxicity, containing a specific glutamine derivative as an active component, and useful for the remedy and prevention of various diseases caused by immunoreaction. CONSTITUTION:The titled agent contains the compound of formula I (R<1>, R<2> and Z are H or alkyl, and at least one of R<1> and R<2> is alkyl) or its salt, e.g. N-4-(1- ethoxycarbonyl-n-propyl)phenyl-L-glutamine. The compound has immunosuppressive activity as well as immunopromoting (activating and promoting) activity, and is useful as a remedy for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, collagen disease, etc., allergic diseases such as asthma, and cancer, infectious diseases, etc. The compound of formula I can be prepared, e.g. by reacting an amino-protected glutamic acid anhydride with an aniline derivative of formula II (Y is alkyl), and removing the protecting group.
PURPOSE:To obtain a safe drug for alleviating hyperlipemia having low toxicity, containing genipin as an active ingredient. CONSTITUTION:The titled drug containing a compound shown by the formula as an active ingredient. The compound shown by formula is obtained from Gardenia jasminoides Ellis f. grandiflora (Lour.) Makino, one Chinese herbal remedy, blended in water of Artenisiae capillaris, detoxifying water of Coptis japonica, Kamikihaiyu or water of Cape jasmine. Gardeniae fructus is obtained by drying fruits of Cape jasmine belonging to the family Rubiaceae. For example, seed and attached tissue of Genipa americana L. are extracted with an ether to give an essence, which is treated with hexane and a tacky oily substance is removed to give a crude genipin fraction. Then crude genipin fraction is subjected to column chromatography to give the compound shown by formula.
Physicians should discuss with patients the appropriate use of avanafil tablets and its anticipated benefits. It should be explained that sexual stimulation is required for an erection to occur after taking avanafil tablets. Patients should be counseled regarding the dosing of avanafil tablets. Inform patients that the recommended starting dose of avanafil tablets is 100 mg, taken as early as approximately 15 minutes before initiation of sexual activity. Based on efficacy and tolerability, the dose may be increased to 200 mg taken as early as approximately 15 minutes before sexual activity, or decreased to 50 mg taken approximately 30 minutes before sexual activity. The lowest dose that provides benefit should be used. Patients should be advised to contact their healthcare provider for dose modification.
High-fat diets (HFDs), a prevailing daily dietary style worldwide, induce chronic low-grade inflammation in the central nervous system and peripheral tissues, promoting a variety of diseases including pathologies associated with neuroinflammation. However, the mechanisms linking HFDs to inflammation are not entirely clear. Here, using a Drosophila HFD model, we explored the mechanism of HFD-induced inflammation in remote tissues. We found that HFDs activated the IMD/NFκB immune pathway in the head through remodeling of the commensal gut bacteria. Removal of gut microbiota abolished such HFD-induced remote inflammatory response. Further experiments revealed that HFDs significantly increased the abundance of Acetobacter malorum in the gut, and the re-association of this bacterium was sufficient to elicit inflammatory response in remote tissues. Mechanistically, Acetobacter malorum produced a greater amount of peptidoglycan (PGN), a well-defined microbial molecular pattern that enters the circulation and remotely activates an inflammatory response. Our results thus show that HFDs trigger inflammation mediated by a bacterial molecular pattern that elicits host immune response.
PURPOSE OF REVIEW: Patients with biochemically recurrent prostate cancer (BCR) after unsuccessful curative therapies frequently have an indolent and asymptomatic disease course for years. There are no prospective data showing that treating BCR improves overall survival despite new imaging strategies and emerging therapeutic data. Managing BCR requires a unique perspective in oncology that balances toxicities and disease kinetics.
RECENT FINDINGS: Prostate specific membrane antigen (PSMA) imaging is now widely available and can define subclinical disease in patients with BCR who otherwise have negative CT and bone scans, but limited data exists showing that treating PSMA-positive disease has long term impact. A phase 3 trial demonstrated that the androgen receptor pathway inhibitor enzalutamide either alone or with androgen deprivation therapy (ADT) was superior in delaying metastasis, relative to ADT alone. Survival benefits from this study remain unknown.
SUMMARY: BCR is a heterogeneous population where overtreatment may present greater risk to patients than a disease course that is often indolent. Management of BCR should be individualized based on disease kinetics. Given the unique biology of BCR, future therapeutic research should emphasize an approach that alters disease trajectory without accompanying side effects and should explore options beyond ADT-based strategies.
A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.
Disclosed is a new combination therapy to treat sickle cell disease (SCD) and thalassemia and their vascular acute and chronic complications by a therapy involving the combined administration of a compound improving HDL particle function and activity (i.e. increasing HDL/ ApoA1 levels), and liposoluble antioxidants xanthophylls (such as lutein, zeaxanthin, meso-zeaxanthin, astaxanthin). This method simultaneously and synergistically restores red blood cell function, normalizes red blood cell membrane cholesterol concentration and decreases oxidative stress both parameters being pathologically affected in SCD, thalassemia and diabetes secondary to low levels of plasma HDL and decreased absorption of dietary lipophilic antioxidant. 
     Although it is known that HDL is involved in the selective and active intestinal uptake of liposoluble vitamins and antioxidants and that HDL uniquely removes excess membrane cholesterol from red blood cells, we discovered that the combination of an HDL therapeutic intervention together with a dietary supplement (as a free or fixed combination) of liposoluble antioxidants act synergistically for treating the rheological complications of sickle cell disease as well as thalassemia and subsequently will contribute to treating and preventing microvascular damages and associated pathologies (retinopathies, kidney failure, leg ulcer, priapism, acute chest syndrome, stroke etc.). Similarly Diabetes, which includes hemorheological abnormalities associated with high red blood cell membrane cholesterol and low plasma HDL antioxidant level will benefit from such combinations. Additional compounds affecting HDL are ApoA1 inducers, HDL and ApoA1 mimetics or (mimicking compounds) ApoA1 and ApoE analogues, Lecithin Cholesterol Acyl Transferase (LCAT) activators, CETP inhibitors and modulators, Peroxisome Proliferator Activated Receptor (PPAR) agonists, ATP Binding Cassette A1 (ABCA1) inducers, Niacin and analogues, Niacin Receptor agonists. Additional lipophilic antioxidants are tocopherols and tocotrienols.
Invention describes producing a chemically well-defined pneumococcal polysaccharide (Pn-Ps) by partial hydrolysis of unpurified Pn-Ps preparation up to predetermined level saving Pn-Ps antigenic properties. Partially hydrolysed Pn-Ps is essentially pure and can be used for producing Pn-Ps immunogenic protein (PRO) conjugate (Pn-Ps-PRO). These Pn-Ps-PRO conjugates exhibit high immunogenic activity. They contain protein complex (OMPC) of outer membrane of Neisseria meningitidis b or its recombinant or purified sub-units, e.g. MIEP, or other immunogenically active proteins which are covalently linked to partially hydrolysed highly pure Pn-Ps intermediate product. The latter is isolated from the most widespread pneumococci. These compounds are useful for prevention of pneumococcal infections in mammals. The conjugates are of particular value to vaccine compositions for inducing anti-pneumococcal immunity in mammals. The most preferable target group can be persons with unfavourable B-cells activity, elder persons and infants till age of two years due to feasibility of these conjugates to cause T-cells reaction. Pn-Ps-OMPC and Pn-Ps-MIEP conjugates are produced in a process containing the following steps: isolation of Ps from capsules of Streptococcus pneumoniae (pneumococci, PN) in culture, partial hydrolysis or mechanical splitting of Pn-Ps, fractionating the said Pn-Ps for obtaining product with smaller molecule size, polydispertion and viscosity, and covalent binding Pn-Ps to OMPC or MIEP.
Increased TNF-α levels following acute myocardial infarction (AMI) contribute to impaired recovery of myocardial function. Interaction of inactive rhomboid protein 2 (iRhom2) with TNF-α converting enzyme (TACE) is required for TNF-α shedding from immune cells. We hypothesized that iRhom2 expression increases in circulating monocytes following AMI. Transcript levels of iRhom2, TACE and TNF-α were evaluated by quantitative real-time PCR in isolated monocytes of 50 AMI patients at admission (d1) and 3 days (d3) after. We observed a significant increase in levels of iRhom2 mRNA expression in monocytes between d1-3, while TNF-α and TACE mRNA expression remained unchanged. At d3, iRhom2 mRNA expression positively correlated with levels of intermediate monocytes or serum TNF-α, and negatively with LV systolic function. iRhom2 may contribute to regulation of post-infarction inflammation and is associated with LV dysfunction following AMI. iRhom2 modulation should be evaluated as a potential therapeutic strategy to attenuate cardiac remodeling following AMI.
Postoperative cognitive dysfunction (POCD) is a common complication after surgery, characterized by deficits in memory, attention and cognitive flexibility. However, the underlying mechanisms of POCD remain unclear. Neuroinflammation and blood-brain barrier disruption have been implicated as potential pathological processes. This study explores the neuroprotective effects and mechanisms of the matrix metalloproteinase(MMP-9)inhibitor GM6001 against POCD. We hypothesize GM6001 may reduce neuroinflammation and preserve blood-brain barrier integrity through direct inhibition of MMP-9. Moreover, GM6001 may stabilize aquaporin-4 polarity and glymphatic clearance function by modulating MMP-9-mediated cleavage of dystroglycan, a key protein for aquaporin-4 anchoring. Our results demonstrate GM6001 alleviates postoperative cognitive deficits and neuroinflammation. GM6001 also preserves blood-brain barrier integrity and rescues aquaporin-4 mislocalization after surgery. This study reveals a novel dual role for MMP-9 inhibition in cognitive protection through direct anti-neuroinflammatory effects and regulating aquaporin-4 membrane distribution. Targeting MMP-9 may represent a promising strategy to prevent postoperative cognitive dysfunction by integrating multiple protective mechanisms.
FIELD: food industry. ^ SUBSTANCE: invention relates to medicine and food industry and may be used to produce biologically active supplements (BAS) with the main reactant produced from cysts of Artemia salina maxillopod. Technical result is achieved by the fact that supplement additionally contains nutmeg fruits ground down to finely dispersed condition and pine nut shell ground down to finely dispersed condition at the following ratio of components, wt %: nutmeg powder - 4-6; powder of pine nut shell - 15-35; powder of dry cysts of Artemia salina - 60-80. Powder of dry cysts of Artemia salina may be ground by available methods and is fractionated so that particle size does not exceed 30 mcm. Soluble substances present in powder of specified dispersion quite easily dissolve in user's gastric juice, insoluble particles produce beneficial effect at intestine walls, cleaning them. Powder of pine nut shell and nutmeg may also be ground and fractionated so that particle size does not exceed 30 mcm. Soluble substances present in powder of specified dispersion quite easily dissolve in user's gastric juice, insoluble particles produce beneficial effect at intestine walls, cleaning them. Invention may be used to produce food supplements as prophylactics agent and as an auxiliary substance in treatment of avitaminosis, obesity, etc. ^ EFFECT: improved biological activity and efficiency, as well as wider range of general health-improving food supplements. ^ 4 cl
The questionnaire created in Phase 1 will be administered to a new group of participants for validation. All partners who are in a relationship with the participants since at least 3 years will be asked to participate in the study for the comparison between participants' and partners' perspectives on the impact of long-term psoriasis on participants' life.
UNLABELLED: Optimal treatment for adhesive small bowel obstruction (SBO) is not defined. Surgery is the only method of treatment for obvious strangulating SBO. Non-operative management (NOM) is widely used among patients with low risk of strangulation, i.e. no clinical, laboratory and CT signs. Randomized controlled trials (RCTs) are recommended to determine the optimal method (early intervention or NOM), but their safety is unclear due to possible delay in surgery for patients needing early intervention.
MATERIAL AND METHODS: A RCT is devoted to outcomes of early operative treatment and NOM for adhesive SBO. The estimated trial capacity is 200 patients. Thirty-two patients were included in interim analysis. In 12 hours after admission, patients without apparent signs of strangulation were randomized into two clinical groups after conservative treatment. Group I included 12 patients who underwent immediate surgery, group II - 20 patients after 48-hour NOM. The primary endpoint was success of non-surgical regression of SBO and reduction in mortality. To evaluate patient safety, we analyzed mortality, complication rates and bowel resection in this RCT with previously published studies.
RESULTS: In group I, all 12 (100%) patients underwent surgery. Only 4 (20%) patients required surgery in group II. Mortality, complication rates and bowel resection rates were similar in both groups. Strangulating SBO was found in 8 (25%) patients. Overall mortality was 6.3%, bowel resection rate - 6.3%, iatrogenic perforation occurred in 3 (18.8%) patients. These values did not exceed previous findings.
CONCLUSION: Non-operative management within 48 hours prevented surgery in 80% of patients with SBO. Interim analysis found no significant between-group differences in mortality, complication rates and bowel resection rate. Patients had not been exposed to greater danger than other patients with adhesive SBO. The study is ongoing.
A method for organizing medical record data based on classification of a set of medical records in accordance with an indexing intervention event identified for each record, associated with a medical intervention. The method is based on extracting for each of a plurality of medical records one or more candidate intervention events, and then mapping these to a dataset (or ontology) of standard intervention event names (indexing intervention events) in order to identify a closest matching indexing event for each extracted intervention event. The mapping is based on breaking down each extracted intervention event into a set of characterizing attributes of particular domains or types and then comparing these with corresponding attribute sets for each of the indexing events in the dataset. A closest match is found, and each medical record is classified according to the closest matching indexing event. Data is then aggregated based on the classifications, and also based on information about a user, e.g. a particular clinical area of expertise.